Myos Rens Technology (Myos Rens Technology) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2020)

View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology 3-Year FCF Growth Rate?

Myos Rens Technology's Free Cash Flow per Share for the three months ended in Sep. 2020 was $-0.55.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Competitive Comparison of Myos Rens Technology's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myos Rens Technology's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's 3-Year FCF Growth Rate falls into.

Myos Rens Technology 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Myos Rens Technology (NAS:MYOS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Myos Rens Technology 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Myos Rens Technology (Myos Rens Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927

Website

https://www.myosrens.com

Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.

Executives

Joseph Mannello	director, officer: Chief Executive Officer	C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel	director	PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri	director	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock	director	C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey	director	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne	director	4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas	director	45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin	10 percent owner
John Nosta	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren	director, 10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc	10 percent owner	150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd	10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019